Skip to content
MarketScale
‹ Back to IndustriesSciences

Virgin Galactic Holdings CEO Michael Colglazier on Space Test Flights

Virgin Galactic Holdings’ recent successful launch rocketed confidence in the viability of commercial space travel. Watch below to see CEO Michael Colglazier react to the launch and comment on efforts to move towards commercial space tourism. Colglazier: We had three big points we were trying to do in this test flight, the first was to…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · BloombergCommercial Space TravelMichael ColglazierSpace
Share

Key takeaways

01

Virgin Galactic Holdings’ recent successful launch rocketed confidence in the viability of commercial space travel.

02

Watch below to see CEO Michael Colglazier react to the launch and comment on efforts to move towards commercial space tourism.

03

Colglazier: We had three big points we were trying to do in this test flight, the first was to…

Virgin Galactic Holdings’ recent successful launch rocketed confidence in the viability of commercial space travel. Watch below to see CEO Michael Colglazier react to the launch and comment on efforts to move towards commercial space tourism.

Colglazier: We had three big points we were trying to do in this test flight, the first was to test a new set of digital controllers that we have for the pilots, give them tighter steering. It worked flawlessly. It went really well as it curved just straight up into space and beautiful flight. Second thing we were doing was to ensure that we had the electromagnetic interference issue from earlier in the year and all the work that we had done on that completely eliminated that problem for us. And then finally, we collected data that we sent over to the FAA and we believe that will give us a great opportunity for them to analyze it, and then hopefully clear our license for commercial flights. So, all in all, just a beautiful day.

Host: Michael, it’s Guy in London. So what’s the journey between now and that points that license being achieved? What needs to happen? When’s the next flight? And what sort of milestones does that. Next slide have to achieve?

Colglazier: Sure well, this was our third flight to space with humans, the first from the state of New Mexico, which is a beautiful, beautiful place to look back down upon the planet. And what follows next. We have three more flights in our test flight program. Our next one will come up with a full crew of mission specialists and back. In addition to our two pilots, that one will be followed with a repeat. But we’re asking our founder, Richard Branson, to come on and really test the private astronaut experience for us. We think, who better to do that? And both of those, we expect to happen this summer. And then that will be followed by our final test flight that’s planned with the Italian Air Force really showcasing how our space systems used for microgravity science research as well as professional astronaut training. And we think that will likely happen late summer or early fall.

Host: So let’s get to that in terms of the preflight training. So we’re going back and forth on this. How healthy do you have to be? What kind of training does there have to be for a regular person to eventually book a flight on this?

Colglazier: So what’s really unique about Virgin Galactic is we take the first 50,000 feet or so with airplane technology. So we take off horizontally and our mother ship climbs out to 40, 45, 50,000 feet. And then from there, the spaceship drops and then rockets up. So it’s powerful, but reasonably smooth because we’ve gone through the heaviest part of the atmosphere, just like you would in a commercial airliner. It’s really important to stay fit in general, but it’s not something that needs years and years of training. So we recommend people stay flexible because they want to be moving around in a weightless environment and kind of looking out all the windows. But generally, we think as long as people are taking care of themselves, lots and lots and lots of people will be able to go with us.

Host: OK, so not much training, Alex was concerned that I was getting a little bit old, maybe I was working so hard to think about. Let’s talk about price. In terms of this venture going forward, Michael. This is a question that I’m surprised I’m asking, but I guess we’ve got to think about it going forward, what is the path to profitability? When do you think this is profitable? Once it starts getting up and running and you kind of get through the initial kind of phase on this and this becomes more commonplace. You got to be making money off this. When do you think you’re going to be making money off this?

Colglazier: Well, the first thing we need to do, obviously, finish this test flight program. And then move into commercial service. And we believe this is going to be a supply constrained business for quite some time. The demand of this is going to be well out in front of our ability to build and scale the fleet up for a while. And as such, it will be reasonably expensive as it goes forward. Our previous 600 people generally had a price around $250,000 each. We have not announced what our pricing will be going forward. We said it will be higher in the beginning. We do see pricing of around $600,000 for per seat equivalent for our microgravity research flights. But again, we have not put pricing out for the private astronaut market.

*Bloomberg contributed to this content

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Video TranscriptExpand ↓

We had three big points we were trying to do in this test flight, the first was to test a new set of digital controllers that we have for the pilots, give them tighter steering. It worked flawlessly. It went really as it curved just straight up into space and beautiful flight. Second thing we were doing was to ensure that we had the electromagnetic interference issue that had the latest from earlier in the year and all the work that we had done on that completely eliminated that problem for us. And then finally, we collected data that we sent over to the FAA and we believe that will give us a great opportunity for them to analyze it, and then hopefully clear our license for commercial flights. So, all in all, just a beautiful day. Michael, it's guy in London. So what's the journey between now and that points that license being achieved? What needs to happen? When's the next flight? What does that. And what sort of milestones does that. Next slide have to achieve? Sure well, this was our third flight to space with humans, the first from the state of New Mexico, which is a beautiful, beautiful place to look back down upon the planet. And what follows next. We have three more flights in our test flight program. Our next one will come up with a full crew of mission specialist and back. In addition to our two pilots, that one will be followed with a repeat. But we're asking our founder, Richard Branson, to come on and really test the private astronaut experience for us. We think, who better to do that? And both of those, we expect to happen this summer. And then that will be followed by our final test flight that's planned with the Italian Air Force really showcasing how our space systems used for microgravity science research as well as professional astronaut training. And we think that will likely happen late summer or early fall. So let's get to that in terms of the preflight training. So we're going back and forth on this. How healthy do you have to be? What kind of training does there have to be for a regular person to eventually book a flight on this? So what's really unique about Virgin Galactic is we take the first $50,000 feet or so with Airplane technology, so we take off horizontally and our mother ship climbs out to 40, 45, 50,000 feet. And then from there, the spaceship drops and then rockets up. So it's powerful, but reasonably smooth because we've gone through the heaviest part of the atmosphere, just like you would in a commercial airliner. It's really important to stay fit in general, but it's not something that needs unique years and years of training. So we recommend people stay flexible because they want to be moving around in a weightless environment and kind of looking out all the windows. But generally, we think as long as people are taking care of themselves, lots and lots and lots of people will be able to go with us. OK, so not much training, Alex was concerned that I was getting a little bit old, maybe I was working so hard to think about. Let's talk about price in terms of this venture going forward, Michael. This is a question that I'm surprised I'm asking, but I guess we've got to think about it going forward, what is the path to profitability? When do you think this is profitable? Once it starts getting up and running and you kind of get through the initial kind of phase on this and this becomes more commonplace. You got to be making money off this. When do you think you're going to be making money off this? Well, the first thing we need to do, obviously, finish this test flight program. And then move into commercial service. And we believe this is going to be a supply constrained business for quite some time. The demand of this is going to be well out in front of our ability to build and scale the fleet up for a while. And as such, it will be reasonably expensive as it goes forward. Our previous 600 people generally had a price around 250,000 each. We have not announced what our pricing will be going forward. We said it will be higher in the beginning. We do see pricing of around $600,000 for per seat equivalent for our microgravity research flights. But again, we have not put pricing out for the private astronaut market.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512